AICentralResources
AI Tool Comparison

Comparing as AI Medical Research & Clinical Decision Support
Atomwise vs Nabla

Atomwise

Atomwise

VS
Nabla

Nabla

Verdict by Category

Detailed category analysis is not available for this comparison.
View Atomwise View Nabla

Detailed Comparison

Feature
Atomwise
Nabla
Pricing
CustomAtomwise operates through enterprise partnership and co-development agreements — there is no self-serve access or published pricing. Collaboration types include: sponsored research agreements (pharma/biotech pays Atomwise to run AI-powered hit discovery campaigns), co-development partnerships (shared IP and milestone/royalty structures), and academic program access for universities through the ATOM initiative. New CEO Steve Worland is also steering Atomwise toward an internal proprietary drug pipeline, which will generate revenue through future licensing and partnering deals as candidates mature into preclinical and clinical stages. Contact Atomwise through atomwise.com for partnership and collaboration inquiries.
FreemiumNabla does not publish exact pricing on its official website; the primary calls-to-action are a free trial (via app.nabla.com) and "Talk to our team" for enterprise sales. Third-party sources consistently report a free tier with usage limits, with paid individual/clinician plans starting around $119/month per provider and higher tiers reported near $239/month per provider. Larger health-system deployments — Nabla's core market, spanning 130+ organizations — are sold via custom enterprise contracts with volume-based pricing, with independent estimates placing typical enterprise rates in the $150-$400/month per provider range depending on scale, EHR integration depth, and features. Exact costs require a sales conversation with Nabla.
Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Productivity ToolsAI Developer APIs & Platforms
Summary
Deep learning for structure-based drug discovery — AtomNet screens 16B+ compounds to find hits for any disease target
Ambient AI that turns patient visits into clinical notes, dictation, and coding — right inside the EHR
Atomwise

Atomwise Pros & Cons

Pros

  • Invented deep learning for structure-based drug discovery in 2012 — true pioneer in the field
  • AtomNet screens 16B+ compounds in under 2 days — fastest virtual screening at this scale
  • 775+ collaborations and 250+ partners — most validated partnership network in AI drug discovery
  • Tackles undruggable targets that traditional methods can't address
  • Strong academic program: 40+ universities including Harvard, Stanford, and Duke
  • New Foundation Model announced 2026 — next-generation AI for molecular discovery
  • $226M+ raised from DCVC, Khosla, Y Combinator, Tencent, B Capital, and Baidu

Cons

  • Early-stage company — no FDA-approved drugs from the platform yet
  • Shifting focus from platform licensing to proprietary pipeline adds execution risk
  • Smaller team (~100-250 employees) compared to larger AI drug discovery peers
  • Revenue still modest at $5-25M range — pre-commercial stage
  • Deep tech focus means long timelines before patient impact is realized
Nabla

Nabla Pros & Cons

Pros

  • Fast note generation, roughly five seconds, that closely mirrors real clinical documentation in independent tests
  • Deep native integration with Epic and other major EHRs rather than copy-paste workflows
  • Broad specialty and language coverage suited to large, diverse health systems
  • Strong compliance posture (HIPAA, SOC 2 Type 2, ISO 27001, GDPR) with configurable data retention
  • Backed by peer-reviewed evidence, including a NEJM AI randomized trial showing documentation-time reductions
  • Combines documentation, dictation, and coding in one platform instead of separate point tools

Cons

  • Pricing isn't published; individuals and smaller practices must go through a sales conversation or rely on third-party estimates to budget
  • Primarily built for hospitals and health systems, so solo clinicians and small practices may find it less tailored than SMB-focused scribes
  • Relies on ambient recording, so encounters where a patient or clinician can't or won't be recorded aren't well supported
  • Some independent reviews note limited customization and quality drop-off on complex, multi-problem visits
  • Mobile app store ratings are mixed and based on a relatively small number of reviews compared to the platform's overall clinician base